Immunotec begins global expansion by strengthening its presence in Latin America

Immunotec, a company specializing in health and wellness through scientific research and the development of dietary supplements, recently announced the start of a global expansion.

The company has a track record of more than 45 years, presence in 17 countries, with 79 global patents, 92 published studies that support the efficiency of its products, and an investment of more than $25 million dollars in research.

All of which are key factors that have led the company to stand out in the global Network Marketing market, valued at almost $201 billion dollars in 2022, and expected to reach $329 billion dollars in 2030.

Increasing operational capacity with key strategies

According to Mauricio Domenzain, CEO of Immunotec, this expansion will allow them to increase their operational capacity, in addition to boosting their growth in Latin America, Europe and North America

“We are about to open France, our fourth opening during 2024 and, in parallel to this expansion, this year we are growing 38% versus the previous year, thus attracting experienced leaders and emerging talent to address new needs,” explains Domenzain.

On the other hand, the CEO said that the goal is to continue strengthening its position in the wellness industry, and they are clear that the only way to achieve this is through strategic actions in key markets, including LatAm.

Million-dollar investment

To support this growth, Immunotec has injected significant resources into infrastructure and support, including a recent $31 million investment to strengthen its operations not only in Mexico, but also in Latin America and globally.

“Of this global investment, we have earmarked $25 million for the construction of a new world-class manufacturing facility in the United States, which will allow us to improve our ability to respond to growing global demand and strengthen our presence in Latin America,” added Domenzain.

The infrastructure expansion is accompanied by another $6 million investment in technology, focused on enhancing its consultants’ tools and technologies, including web platform upgrades and the development of a dedicated application.

To conclude, the company’s CEO indicated that Immunotec continues to consolidate its presence by having a base of thousands of consultants globally, a number that is growing steadily, allowing it to stand out in the direct sales sector.

“Thanks to our investments in innovation, operational improvement and deepening product research, Immunotec is well positioned to meet the evolving needs of our consultants and customers around the world,” said Domenzain.